These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 25469850)

  • 21. [Immunoglobulin light chain amyloidosis: recent molecular, clinical and therapeutic approach].
    Thierry A; Bridoux F; Goodman H; Belmouaz S; Abou Ayache R; Desport E; Jaccard A; Touchard G
    Nephrologie; 2004; 25(4):111-8. PubMed ID: 15291138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac amyloidosis: a practical approach to diagnosis and management.
    Kapoor P; Thenappan T; Singh E; Kumar S; Greipp PR
    Am J Med; 2011 Nov; 124(11):1006-15. PubMed ID: 22017778
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
    Merlini G; Ascari E; Amboldi N; Bellotti V; Arbustini E; Perfetti V; Ferrari M; Zorzoli I; Marinone MG; Garini P
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2959-63. PubMed ID: 7708755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic amyloidosis: novel therapies and role of biomarkers.
    Nuvolone M; Merlini G
    Nephrol Dial Transplant; 2017 May; 32(5):770-780. PubMed ID: 27540044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
    Sekijima Y
    Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Light Chain 6aJL2-R24G Amyloid Fiber Formation Associated with Light Chain Amyloidosis.
    Pelaez-Aguilar AE; Rivillas-Acevedo L; French-Pacheco L; Valdes-Garcia G; Maya-Martinez R; Pastor N; Amero C
    Biochemistry; 2015 Aug; 54(32):4978-86. PubMed ID: 26214579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Characterization of amyloidosis].
    Yazaki M; Ikeda S
    Brain Nerve; 2014 Jul; 66(7):723-30. PubMed ID: 24998817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloidosis.
    Pinney JH; Hawkins PN
    Ann Clin Biochem; 2012 May; 49(Pt 3):229-41. PubMed ID: 22402917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. From renal amyloid deposits to the identification of the culprit genes.
    Pirson Y
    J Nephrol; 2003; 16(3):427-30. PubMed ID: 12832746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Amyloidosis].
    Homma N
    Nihon Rinsho; 2004 May; 62 Suppl 5():607-11. PubMed ID: 15197994
    [No Abstract]   [Full Text] [Related]  

  • 32. Once AL amyloidosis: not always AL amyloidosis.
    Jhaveri T; Sarosiek S; Ruberg FL; Siddiqi O; Berk JL; Sanchorawala V
    Amyloid; 2018 Jun; 25(2):139-140. PubMed ID: 29516761
    [No Abstract]   [Full Text] [Related]  

  • 33. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met.
    Tsuchiya-Suzuki A; Yazaki M; Kametani F; Sekijima Y; Ikeda S
    Hum Pathol; 2011 Feb; 42(2):236-43. PubMed ID: 21056899
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
    Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
    Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Familial amyloidotic polyneuropathy and transthyretin.
    Nagasaka T
    Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiac amyloidosis.
    Quarta CC; Kruger JL; Falk RH
    Circulation; 2012 Sep; 126(12):e178-82. PubMed ID: 22988049
    [No Abstract]   [Full Text] [Related]  

  • 37. [Progress in the diagnosis and treatment of cardiac amyloidosis].
    Jurczyszyn A; Engel A; Rajzer M; Czepiel J; Mazurs G
    Przegl Lek; 2014; 71(6):340-5. PubMed ID: 25344976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
    Palladini G; Dispenzieri A; Gertz MA; Kumar S; Wechalekar A; Hawkins PN; Schönland S; Hegenbart U; Comenzo R; Kastritis E; Dimopoulos MA; Jaccard A; Klersy C; Merlini G
    J Clin Oncol; 2012 Dec; 30(36):4541-9. PubMed ID: 23091105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted treatment for amyloidosis.
    Pepys-Vered ME; Pepys MB
    Isr Med Assoc J; 2014 May; 16(5):277-80. PubMed ID: 24979830
    [No Abstract]   [Full Text] [Related]  

  • 40. Nephelometric measurement of human serum prealbumin and correlation with acute-phase proteins CRP and SAA: results in familial amyloid polyneuropathy.
    Connors LH; Gertz MA; Skinner M; Cohen AS
    J Lab Clin Med; 1984 Oct; 104(4):538-45. PubMed ID: 6090552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.